N
RAPP

Nuveen’s Rapport Therapeutics RAPP Stock Holding History

Nuveen’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Buy
71,508
+562
+0.8% +$15.8K ﹤0.01% 2238
2025
Q4 		$2.15M Buy
70,946
+49,073
+224% +$1.36M ﹤0.01% 2263
2025
Q3 		$650K Hold
21,873
– – ﹤0.01% 2807
2025
Q2 		$249K Hold
21,873
– – ﹤0.01% 3107
2025
Q1 		$219K Buy
21,873
+9,805
+81% +$127K ﹤0.01% 3117
2024
Q4 		$214K Hold
12,068
– – ﹤0.01% 3194
2024
Q3 		$247K Buy
+12,068
New +$259K ﹤0.01% 3182

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Nuveen's RAPP Position: Q1 2026 in Review

Nuveen increased its Rapport Therapeutics (RAPP) stake by 0.79% in Q1 2026, buying an estimated $15.8K and bringing the position to 71,508 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Nuveen first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Nuveen held 71,508 shares of Rapport Therapeutics worth $2.24M as of Q1 2026.
  • Nuveen bought 562 Rapport Therapeutics shares in Q1 2026, an estimated $15.8K.
  • Rapport Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2238 holding.
  • Nuveen first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.